Drug intelligence / Profile preview

5-methoxy-2-aminoindane

Development stage
Phase 2
Lead developer
Clearmind Medicine
Modality
Small Molecules
Administration
Oral
01

Overview

5-methoxy-2-aminoindane (MEAI) is a synthetic psychoactive compound belonging to the aminoindane class. It acts as a modestly selective serotonin releasing agent (SSRA), with approximately six-fold selectivity for serotonin over norepinephrine and about twenty-fold over dopamine. MEAI also exhibits moderate affinity for the \u03b1\u2082-adrenergic receptor. Its pharmacological profile suggests entactogenic and sympathomimetic effects similar to MDMA but with potentially lower misuse liability. The compound has been investigated for its potential in reducing alcohol consumption and binge drinking behavior due to its reported ability to induce mild euphoria and an alcohol-like "tipsy" experience while decreasing the desire for further alcohol intake. Preclinical studies have also explored its effects on metabolic syndrome and obesity[1][8][10].

Brand names
Pace (historical, not current)Chaperon (historical)
Other names
2-amino-5-methoxyindan2-amino-5-methoxyindaneChaperon5-Methoxy-2-indanamin5-Méthoxy-2-indanamine5-Methoxyindan-2-ylamine
02

Targets

ADRA2A (α2A)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on 5-methoxy-2-aminoindane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-methoxy-2-aminoindane.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call